title: Adverse Events in HIV-Infected Persons Receiving Antiretroviral Drug Regimens in a Large Urban Slum in Nairobi, Kenya, 2003-2005.
abstract: OBJECTIVE
  This article describes toxicities to antiretroviral therapy (ART) among HIV-infected patients receiving care at a clinic in a large urban slum in Nairobi, Kenya.
  
  
  METHODS
  Patients were treated with nonnucleoside reverse transcriptase inhibitor-based ART and followed at scheduled intervals. Frequencies and cumulative probabilities of toxicities were calculated.
  
  
  RESULTS
  Among 283 patients starting ART, any and severe clinical toxicity were recorded as 65% and 6%, respectively. Cumulative probabilities for remaining free of any and severe clinical toxicities at 6, 12, and 18 months, were 0.47, 0.26, and 0.17, respectively and 0.98, 0.95, and 0.89, respectively. The probability of remaining free from elevated and grade 3 or 4 serum aminotransferase (AST) at 6, 12, and 18 months were 0.62, 0.42, and 0.21, respectively, and 0.99 at 6, 12, and 18 months.
  
  
  CONCLUSIONS
  ART toxicities were frequent, but severe toxicities were less common. In resource-limited settings, ART toxicity should not represent a barrier to care.
authors.affiliation: Global AIDS Program, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia 30333, USA. aakim@cdc.gov
authors.forename: Andrea A
authors.initials: AA
authors.lastname: Kim
authors.forename: Lucy
authors.initials: L
authors.lastname: Wanjiku
authors.forename: Doris K
authors.initials: DK
authors.lastname: Macharia
authors.forename: Mary
authors.initials: M
authors.lastname: Wangai
authors.forename: Anthony
authors.initials: A
authors.lastname: Isavwa
authors.forename: Hussein
authors.initials: H
authors.lastname: Abdi
authors.forename: Barbara J
authors.initials: BJ
authors.lastname: Marston
authors.forename: Festus
authors.initials: F
authors.lastname: Ilako
authors.forename: Mette
authors.initials: M
authors.lastname: Kjaer
authors.forename: Kenneth
authors.initials: K
authors.lastname: Chebet
authors.forename: Kevin M
authors.initials: KM
authors.lastname: De Cock
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Weidle
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D007630:Kenya; D011204:Poverty Areas; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors